Abstract: Herein are described data acquisition systems and methods applying such systems to determine three-dimensional (3D) diffusion tensors, and simultaneously, to perform 3D structure imaging. Example data acquisition systems can include computing systems in communication with modified light sheet microscopes that are configured for high-speed volumetric imaging to record 3D diffusion processes and high-resolution 3D structural imaging.

Abstract: Provided are a pharmaceutical composition of (S)-ketorolac and a preparation method therefor, which belong to the technical field of pharmaceutical preparations. The pharmaceutical composition includes (S)-ketorolac or a pharmaceutically acceptable salt thereof, a stabilizer, a pH-adjusting agent, and an excipient, and the dosage form of the pharmaceutical composition is preferably lyophilized powder injection. The lyophilized powder injection prepared herein has optical purity of an active ingredient greater than or equal to 95% after being stored under long-term stability test conditions for 6 months and optical purity of an active ingredient greater than or equal to 90% after being stored under accelerated stability test conditions for 6 months. The lyophilized powder injection has important use in the preparation of non-steroidal anti-inflammatory drugs with analgesic, anti-inflammatory, antipyretic effects.

Abstract: A ketorolaco derivative as shown in formula (I) has a better half-life and stability, has good pharmacokinetic properties, and has a higher stability in vitro; and as a preparation, the ketorolaco derivative can enhance efficacy and reduce toxicity. The present invention well improves the defects of frequent administration, gastrointestinal side effects, poor compliance and the like in traditional ketorolaco preparations.

Abstract: The application related to an ibuprofen ester derivative and an emulsion preparation thereof. A carboxyl group of racemic ibuprofen or S-ibuprofen is derivatized so that Compound N9 and a dextrorotatory enantiomer N9(S) thereof are obtained and further prepared into an emulsion preparation, which overcomes the problems of safety and compliance of patients existing in clinical application of existing ibuprofen/dexibuprofen injections and achieves the purposes of reducing vascular irritation, increasing clinical use approaches, and improving the stability of preparations in clinical applications.

Abstract: Provided is an ibuprofen ester prodrug represented by Structural Formula (1), a racemate, stereoisomer or pharmaceutically acceptable salt or solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof. Further provided are a method for preparing the compound, a pharmaceutical composition containing the compound, and an application of the compound in preparation of nonsteroidal anti-inflammatory drugs. The pharmaceutical composition containing the ibuprofen ester prodrug may be prepared into fat emulsion injection preparations. The ibuprofen ester prodrug has good stability and good pharmacokinetic properties and overcomes the problems of ibuprofen such as a short half-life, poor stability, irritation, and incompatibility.

Abstract: Provided are an arylpropionic acid derivative represented by Formula (I), a pharmaceutical composition and a preparation method and an application thereof. The arylpropionic acid derivative has a good half-life, pharmacokinetic property and in vitro stability and can enhance efficacy and reduce toxicity after formulated into preparations, which repairs the defects of frequent administration, gastrointestinal side effects and poor patient compliance of traditional nonsteroidal anti-inflammatory drugs.

Abstract: The invention provides histone deacetylase (HDAC) inhibitors shown as Formula I, where R1 to R8 are as defined in the specification. The invention also provides methods for synthesis of these compounds and applications of these compounds in preparing pharmaceuticals for preventing or treating mammal diseases related to the dysregulation of HDAC.

Abstract: The invention provides histone deacetylase (HDAC) inhibitors shown as Formula I, where R1 to R8 are as defined in the specification. The invention also provides methods for synthesis of these compounds and applications of these compounds in preparing pharmaceuticals for preventing or treating mammal diseases related to the dysregulation of HDAC.

Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.

Abstract: The present invention provides a unit dose treatment product comprising: a) a sealed disposable package comprising a laminate wherein the laminate comprises; i) an aluminium barrier layer; and ii) a polymer contact layer selected from polypropylene, polyamide and nylon 12; b) a liquid treatment product contained within the package, wherein the liquid treatment product comprises: i) a film-forming polymer; ii) an organic solvent for the film-forming polymer having a boiling point of less than 150° C. and a solubility parameter of less than 22 (MPa)0.5; and iii) an active agent; wherein the polymer contact layer of the laminate is in contact with the liquid treatment product. Kits comprising the unit dose treatment products and methods of treating the tissues of the oral cavity employing the unit dose treatment products are also provided. The products, kits and methods herein provide for convenient oral treatments, especially tooth whitening treatments using an extended regimen.

Abstract: Disclosed is a process for indicating the presence of soluble fluoride ions in oral care compositions comprising making a signal solution and then bringing the signal solution into contact with an oral care composition and a color change occurs if an effective amount of soluble fluoride ion is present in the oral care composition. Further disclosed are test compositions for use in such process.

Abstract: A hard disk mounting assembly includes a chassis (10), a first cage (20) mounted to the chassis, a hard disk drive(40) (HDD) and a second cage (60). The HDD defines a plurality of fixing openings (42). The first cage includes a plurality of mounting pillars (28) resilient connected with the cage and received in the fixing openings of the HDD at one end portion. The first cage further defines a pair of engaging apertures (34) at opposite sides thereof. The second cage has a base (62) and two connecting arms (68) depending from the base. the base forms a plurality of elastic fingers (66). The first cage is mounted to the chassis and the HDD is received in the first cage, the second cage hitches the first cage by the connecting arms with the elastic fingers pressing the HDD, thereby mounting the HDD to the chassis.

Abstract: The present invention provides a unit dose treatment product comprising:

Abstract: Disclosed is a delivery system for delivering an oral care substance to the oral cavity, the delivery system comprising: (a) a removable backing strip having sufficient flexibility so as to be readily conformable to an oral surface when the delivery system is placed thereagainst; and (b) an oral care composition applied to the strip of material such that when the delivery system is placed on the oral surface the oral care composition contacts the oral surface, the oral care composition comprising: (i) an organosiloxane resin; (ii) a theology modifier; and (iii) at least one oral care substance; wherein the oral care composition remains on the oral surface after the backing strip is removed. Further disclosed are such delivery systems in which the oral care composition further comprises fluid diorganopolysiloxane-based polymers; such compositions may further comprise carriers for solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymers.

Abstract: Disclosed is a process for indicating the presence of soluble fluoride ions in oral care compositions comprising making a signal solution and then bringing the signal solution into contact with an oral care composition and a color change occurs if an effective amount of soluble fluoride ion is present in the oral care composition. Further disclosed are test compositions for use in such process.

Abstract: Disclosed is a delivery system for delivering an oral care substance to the oral cavity, the delivery system comprising: (a) a removable backing strip having sufficient flexibility so as to be readily conformable to an oral surface when the delivery system is placed thereagainst; and (b) an oral care composition applied to the strip of material such that when the delivery system is placed on the oral surface the oral care composition contacts the oral surface, the oral care composition comprising: (i) an organosiloxane resin; (ii) a theology modifier; and (iii) at least one oral care substance; wherein the oral care composition remains on the oral surface after the backing strip is removed. Further disclosed are such delivery systems in which the oral care composition further comprises fluid diorganopolysiloxane-based polymers; such compositions may further comprise carriers for solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymers.